TSLA
Tesla
-- 292.980 MSTR
Strategy
-- 255.430 NVDA
NVIDIA
-- 124.920 MARA
MARA Holdings
-- 13.920 COIN
Coinbase
-- 215.620 
NEWS
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Tuesday, 10th December at 9:00 am
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxtecan-nxki (ENHERTU®)
Combination therapy was well tolerated with a manageable safety profile consistent with prior experience with each investigational agent
Data contribute to growing evidence supporting evorpacept activity in combination with anti-HER2-targeted agents among patients with HER2-positive cancers
Tuesday, 10th December at 9:00 am
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxtecan-nxki (ENHERTU®)
Combination therapy was well tolerated with a manageable safety profile consistent with prior experience with each investigational agent
Data contribute to growing evidence supporting evorpacept activity in combination with anti-HER2-targeted agents among patients with HER2-positive cancers
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment